Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LONDON, September 29 /PRNewswire/ --

- Award Winning 'best eBay alternative' invests to strengthen worldwide businesses

Offering online sellers and buyers the chance to make money and find a bargain, eBid.net, today announces its expansion into Portugal, Norway, Denmark and Sweden increasing its global presence to 18 territories across UK, the US and Canada, Africa, Asia and Australasia.

LEUVEN, Belgium, September 29 /PRNewswire/ --

- Results Presented at World Stroke Congress in Vienna

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. The trial showed that microplasmin was generally well tolerated and also provided some interesting preliminary efficacy data. The overall results of the study were presented by Dr. Vincent Thijs on September 27 at a Late-Breaking Clinical Trial session at the World Stroke Congress.

MILTON KEYNES, England, September 29 /PRNewswire/ --

- With Photo

A reminder has gone out to rabbit owners who took part in the first ever National Vaccination Month (March 2008) that they will need to vaccinate their pets this month in order to maintain immunity to myxomatosis.

Under the National Vaccination Month campaign owners of unvaccinated or overdue pet rabbits were offered a free dose of vaccine to protect their pets against myxomatosis - the first was given in March and the second is due now.

Currently less than one in ten owners ensure their rabbit is vaccinated against myxomatosis, a devastating killer disease spread by biting insects, which appears to be on the increase.

LONDON, September 29 /PRNewswire/ --

- Businessman Launches Campaign to Ban Bullet Points and Give Work More Wit

- With Photo

Businessman Jon Moon today launched a nationwide campaign to ban bullet points from work. "We all use bullet points because we always have, yet they don't work. They don't break up dull text. They are dull text," he says. Jon, who advises companies on clarity in written and visual communications, wants us to end our love affair with black dots and instead use WiT (Words in Tables), his new way of showing information in reports and slides. "WiT has three times more impact than bullets, and it does a fantastic CV too," Jon continues.

MONTPELLIER, France, September 29 /PRNewswire/ -- AwoX, a leading provider of network entertainment solutions, today announced the signature of a distribution agreement with Japan-based Network Technology Co., Ltd.. Under the terms of this agreement, Network Technology will sell, distribute and support AwoX middleware solutions for networked audio/video applications in Japan.

WORCESTER, Massachusetts, September 26 /PRNewswire/ --

Verax Biomedical Inc., a pioneer of rapid tests for detecting bacterial contaminants in blood cells and tissue, announced its Platelet PGD(R) Test for bacterial detection is now CE Marked. The test, which received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) in September 2007, holds potential to improve the safety of the blood supply by easily and quickly detecting a broad range of bacterial contaminants.